Management discuses results from the Phase 3 BOND-003 Trial of Cretostimogene Monotherapy in high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) on a conference call to be held on April 28 at 8 am. Webcast Link
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGON:
- CG Oncology announces Phase 3 BOND-003 data presented at AUA meeting
- CG Oncology’s Promising Phase 3 Data and Market Potential Justify Buy Rating
- CG Oncology initiated with a Sector Perform at Scotiabank
- Buy Rating Affirmed for CG Oncology Amid Promising Trial Data and Market Opportunities
- Buy Rating for CG Oncology, Inc. Driven by Promising Developments in Bladder Cancer Treatment